



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		Complete If Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/763479		
		Filing Date	January 23, 2004		
		First Named Inventor	Vivek Mittal		
		Art Unit	1645-1633		
		Examiner Name	Not Yet Assigned Marvich		
Sheet	1	of	2	Attorney Docket Number	CSHL-P01-012

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
MM	AA	US-2002/0177564-A1	12-28-2002	Evans et al.	
	AB	US-6,333,318	12-25-2001	Evans et al.	
	AC	US-6,245,531	06-12-2001	Hogness et al.	
	AD	US-6,610,828	08-26-2003	Jepson et al.	
	AE	US-6,258,603	07-10-2001	Carlson et al.	
	AF	US-2001/0044151	11-22-2001	Carlson et al.	
	AG	US-2003/0088890	05-08-2003	Albertsen et al.	
	AH	US-2003/0110528	06-12-2003	Albertsen et al.	
	AI	US-2002/0187972-A1	12-12-2002	Evans et al.	
	AJ	US-2002/0119521-A1	08-29-2002	Palli et al.	
	AK	US-2002/0065243-A1	05-30-2002	Fung et al.	
	AL	US-2003/0220286-A1	11-27-2003	Abruzzese et al.	
MM	AM	US-6,251,640	06-26-2001	Yao	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
WMA	BA	WO-97/38117	10-16-1997	Evans et al.		
	BB	WO-96/37609	11-28-1996	Jepson et al.		
	BC	WO-01/70816	09-27-2001	Palli et al.		
	BD	WO-02/066612	08-29-2002	Palli et al.		
	BE	WO-02/066614	08-29-2002	Palli et al.		
WMA	BF	WO-02/088346	11-07-2002	Massie et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind's Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MM	CA	WIZNEROWICZ et al., Conditional Suppression of Cellular Genes: Lentivirus Vector-Mediated Drug-Inducible RNA Interference, 2003. J Virol.;77(16):8957-61	
	CB	CZAUDERNA F et al., Inducible shRNA expression for application in a prostate cancer mouse model, 2003. Nucleic Acids Res. 31(21):e127	
	CC	VAN DE WETERING et al., Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector, 2003. EMBO Rep.;4(6):609-15	
	CD	OHKAWA et al., Control of the Functional Activity of an Antisense RNA by a Tetracycline-Responsive Derivative of the Human U6 snRNA Promoter, 2000. Human Gene Therapy 11(4):577-685	
	CE	SAEZ et al., Inducible gene expression in mammalian cells and transgenic mice, 1997. Current Opinion in Biotechnology 8: 608-616	
Examiner Signature	Marvich		Date Considered

MM	CF	BOYD et al., In vivo footprinting studies suggest a role for chromatin in transcription of the human 7SK gene, 2000. <i>Gene</i> 244:33-44	
	CG	BODEN et al., Promoter choice affects the potency of HIV-1 specific RNA interference, 2003. <i>Nucleic Acids Res.</i> 31(17):5033-8	
	CH	XIA et al., An enhance U6 promoter for synthesis of short hairpin RNA, 2003. <i>Nucleic Acids Res.</i> 31(17):100	
	CI	ELBASHIR et al., Analysis of gene function in somatic mammalian cells using small interfering RNAs, 2002. <i>Methods</i> 26, 199-213.	
	CJ	PADDISON et al., Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells, 2002. <i>Genes Dev</i> 16, 948-58.	
	CK	SUI et al., A DNA vector-based RNAi technology to suppress gene expression in mammalian cells, 2002. <i>Proc Natl Acad Sci U S A</i> 99, 5515-20	
	CL	BRUMMELKAMP et al., A system for Stable Expression of Short Interfering RNAs in Mammalian Cells, 2002. <i>Science</i> 296, 550-3	
	CM	PAUL et al., Effective expression of small interfering RNA in human cells, 2002. <i>Nat Biotechnol</i> 20, 505-8	
	CN	RUBINSON et al., A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference, 2003. <i>Nat Genet</i> 33, 401-6	
	CO	GOSSEN et al., Transcriptional Activation by Tetracyclines in Mammalian Cells, 1995. <i>Science</i> 268, 1766-9	
	CP	NO et al., Edysone-inducible gene expression in mammalian cells and transgenic mice, 1996. <i>Proc Natl Acad Sci U S A</i> 93, 3346-51	
	CQ	CRAENENBROECK et al., Evaluation of the tetracycline- and ecdysone-inducible systems for expression of neurotransmitter receptors in mammalian cells, 2001. <i>Eur J Neurosci</i> 14, 968-76	
	CR	STOLAROV et al., Design of a retroviral-mediated ecdysone-inducible system and its application to the expression profiling of the PTEN tumor suppressor, 2001. <i>Proc Natl Acad Sci U S A</i> 98, 13043-8	
	CS	LIN, et al., Spatially Discrete, Light-Driven Protein Expression, 2002. <i>Chem Biol</i> 9, 1347-53	
	CT	DAS et al., Basal promoter elements as a selective determinant of transcriptional activator function, 1995. <i>Nature</i> 37:657-660	
	CU	KARNS et al., Manipulation of gene expression by an ecdysone-inducible gene switch in tumor xenografts, 2001. <i>BMC Biotechnology</i> 1, 11	
	CV	CARMELL et al., Germine transmission of RNAi in mice, 2003. <i>Nat Struct Biol</i> 10, 91-2.	
MM	CW	MEISSNER et al., Development of an inducible pol III transcription system essentially requiring a mutated form of the TATA-binding protein, 2001. <i>Nucleic Acids Research</i> 29(8), 1672-1682	

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

9364891.1



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/763479
				Filing Date	January 23, 2004
				First Named Inventor	Vivek Mittal
				Art Unit	1633
				Examiner Name	M. Marvich
Sheet	1	of	1	Attorney Docket Number	CSHL-P01-012

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
MM	BG	WO 02/24899	03-28-2002	VALENTIS et al.		
MM	BH	WO 02/08098	10-31-2002	UNIV. VIRGINIA PATENT FOUNDATION		
MM	BI	WO 04/080378	09-23-2004	UNIVERSITE DE NICE		
MM	BJ	WO 05/007877	01-27-2005	UNIVERSITY OF MASSACHUSETTS		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MM	CX	PADDISON PJ et al., "RNA interference: the new somatic cell genetics?" Cancer Cell: 2(1): 17-23, 2002.	
MM	CY	GUPTA et al., "Inducible, reversible, and stable RNA interference in mammalian cells", Proc Natl. Acad. Sci. US A. 2004 Feb 17; 101(7):1927-32. Epub 2004 Feb 4	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	M. Marvich	Date Considered	4/26/07
-----------------------	------------	--------------------	---------

9826352_1